Drugs / BW-20507
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07595159 | Jun 2024 → Nov 2025 | chronic hepatitis B virus infection | Shanghai Argo Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07135349 | Sep 2025 → Jun 2026 overdue | chronic hepatitis B virus infection | Shanghai Argo Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BW-20507 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07595159 ↗ |
| Route | Subcutaneous | “administered one dose of BW-20507 or placebo subcutaneously” NCT07595159 ↗ |